trans-septal puncture (TSP) is routinely performed to gain access to the left heart. TSP causes an iatrogenic atrial septal defect (ASD) with a transient right-to-left shunt which can predispose patients to stroke and migraine. 4 In 2 different studies, the incidence of migraine after TSP was 0.5% and 2.2%, respectively, and the migraine was transient and resolved without any consequence. 3, 4 In a separate study, complete resolution or improvement of migraine was noticed with the ASD/ patent foramen ovale closure. 5 Additional case reports have accounted AF occurring during episodes of migraine with aura where the cardiac rhythm was normal in between episodes. 6 All these reports evidently demonstrate an indeterminate association between AF, TSP during radiofrequency CA, and migraine. Besides, it is not yet explored whether a successful CA of AF has any impact on the natural course of pre-existing or newly occurring migraine, except 1 study by Noheria et al 7 where they observed high prevalence (2.3%) of postprocedural headaches which included new-onset migraine and worsening of pre-existent migraine after AF ablation but acknowledged the calculation to be a crude estimate which was solely based on subjective recall of headache frequency. We hypothesized that in the absence of cerebrovascular events, CA has no negative impact on the disease course of migraine and evaluated the influence of ablation therapy on the incidence and clinical course of migraine in AF patients with or without a previous history, using standardized migraine questionnaire as well as comparing magnetic resonance imaging (MRI)-measured brain lesions before and after the ablation procedure.
Additionally, several isolated case studies have reported improvement in the frequency and severity of migraine during treatment with warfarin. 8, 9 Warfarin is routinely prescribed to patients undergoing radiofrequency CA to prevent thromboembolic events. Therefore, our study also explored the impact of therapeutic warfarin on the prevalence and clinical course of migraine in patients with or without a previous history.
Methods
Consecutive patients presenting for AF ablation at our center from April 2011 to May 2013 were screened for enrollment into this prospective study. The basic criteria for entering into the study were as follows: age 18 to 75 years, willingness to undergo pre-and postablation diffusion MRI (dMRI), no history of stroke, transient ischemic attacks, epilepsy or uncontrolled hypertension, and no contraindication for dMRI. Based on prior history of migraine, consenting patients were classified into 2 groups. Of the 1210 total patients screened, 40 patients with an established diagnosis of migraine were included in group 1 (migraine group: age, 64±9 years; men, 75%; 30% paroxysmal AF; 33% persistent AF; and 38% long-standing persistent AF) and 85 patients without migraine history were enrolled as group 2 (no-migraine group: age, 61±10 years; men, 73%; 33% paroxysmal AF; 29% persistent AF; and 38% long-standing persistent AF). Current migraine status was evaluated using a standardized questionnaire adopted by American Migraine Center (http://americanmigrainecenter.com/pretreatment-questionnaire/). 10 A systematic clinical neurological examination by the attending cardiologist (including cranial nerve, motor and sensory function, and gait assessment) was performed at admission and the day after the procedure (before discharge). dMRI of brain was performed for all at baseline and 24 hours post procedure. Follow-up migraine survey was conducted at 6 and 12 months post ablation. Additionally, health-related quality of life (QoL) was assessed at baseline and 6 and 12 months of procedure, using Medical Outcome Study Short Form-36 (SF-36; Figure 1 ).
Migraine Questionnaire
This self-reported survey was used to determine the migraine status of the patients at baseline and follow-up. It includes questions that directly enquired about the presence and frequency of migraine headaches, duration of episodes, and intensity of pain (in a scale of 
WHAT IS KNOWN
• New-onset migraine rarely occurs after procedures involving transseptal puncture.The association between hypercoagulability and migraine is well documented.
• Autonomic dysfunction seems to be involved in the pathophysiology of both migraine and atrial fibrillation and is affected by catheter ablation of atrial fibrillation.
WHAT THE STUDY ADDS
• In this prospective study, catheter ablation of atrial fibrillation under a therapeutic international normalized ratio was usually associated with an improvement in migraine symptoms in patients with a history of migraine and no new development of migraine headaches in those without such a history.
• The 4 cases of new migraine or aggravation of pre-existent headache occurred in patients who had subtherapeutic periprocedural anticoagulation and evidence of silent cerebral embolization on MRI. 0-10 with 10 being the worst); accompaniment of any of the 5 characteristics of migraine, such as nausea/vomiting, unilateral location, photophobia, visual disturbance, and unilateral numbness preceding headache; 11 and factors aggravating or relieving the symptoms, migraine-specific treatment history, and how the condition affects their QoL. Patients were diagnosed as having definite migraine if they had moderate to severe repeat headaches of pulsating in nature without any known cause, which was aggravated by or causing avoidance of routine physical activity, such as climbing stairs, plus presence of any 1 of the above-mentioned 5 features of migraine. 7 The diagnosis was confirmed by neurology referral. Migraine was classified as new-onset when the symptoms were experienced for the first time after the ablation procedure without any previous history, recent, or remote. Patients were asked to maintain a headache diary for easy recall of symptom details while responding to the questionnaire at follow-ups.
QoL Survey
SF-36, the most widely used generic questionnaire to measure QoL, assesses 8 aspects of health status, namely physical functioning, role limitations because of physical health, mental health, role limitations because of emotional problem, social functioning, bodily pain, general health, and vitality. All responses were scored on a scale from 0 to 100, with 100 representing the best possible functioning status. 12
Diffusion-Weighted MRI
Imaging was performed at baseline and 24 hours post procedure on a 1.5-T GE Signa scanner (General Electric, Milwaukee, WI) with a maximum gradient strength of 22 m/Tm. No contrast dye was used.
Lesions were identified on the diffusion-weighted imaging and correlated with T2/fluid-attenuated inversion recovery images to increase diagnostic confidence. A diffusion-weighted imaging scan was considered positive if it revealed an area of hyperintensity on diffusion-weighted imaging and hypointensity on apparent diffusion coefficient maps relative to the normal brain. All dMRI images were read and interpreted by the same neuroradiologist to avoid any disparity in opinion. The neuroradiologist was blinded to the clinical status and identity of the patients and reported all scans at the end of the study.
Lesions were described as silent cerebral infarcts (SCIs) if abnormal MRI of the brain was detected in the setting of a normal neurological examination without a history or physical findings associated with an overt stroke. 13 The study was approved by Institutional Review Board (IRB) of our institution (Clinicaltrials.gov ID: NCT01391091).
Ablation Procedure
Standard institutional protocol was followed for the ablation procedure as described in earlier publications from our group. 13 Briefly, antiarrhythmic drugs were discontinued 4 to 5 half-lives before ablation. In case of paroxysmal AF, pulmonary vein antrum isolation was performed. In patients with non-paroxysmal AF, pulmonary vein antrum isolation was extended to the entire posterior wall down to the coronary sinus and to the left part of the septum. Complex fractionated atrial electrograms were ablated on detection. After ablation, isoproterenol challenge (≤30 μg/min) was performed to reveal nonpulmonary vein triggers or disclose pulmonary vein reconnection. Non-pulmonary vein triggers were ablated using additional radiofrequency energy.
Anticoagulation Protocol
All patients remained on warfarin for 8 to 10 weeks before the ablation and a therapeutic international normalized ratio (INR) of 2 to 3 for 4 weeks before ablation was requested. However, patients with subtherapeutic INR on the day of the procedure were included in the study. Details of warfarin therapy are provided below.
During Procedure 13
The treating physicians decided the periprocedural anticoagulation regimen based on their preference. Eighty-eight (70%) patients underwent ablation procedures with continuous warfarin therapy (on-Coumadin) and 37 (30%) had the procedure with warfarin discontinuation (off-Coumadin).
Off-Coumadin
Warfarin was discontinued 3 days before the ablation procedure, and enoxaparin 1 mg/kg was administered twice a day until 12 hours before the procedure. An intravenous bolus of heparin 15 000 IU was given before the TSP. During the procedure, the infusion rate of heparin was adjusted to keep the activated clotting time in the range of 300 to 450 seconds. The trans-septal sheaths were continuously infused with heparinized saline (2000 IU/ 250 mL bag) during the entire procedure. All patients underwent transesophageal echocardiography before the ablation to rule out the presence of left atrial thrombus. At the end of the procedure, the heparin infusion was discontinued, and anticoagulation was reversed with protamine. Warfarin was restarted in the evening of the procedure. In addition, enoxaparin 0.5 mg/kg bid was routinely started ≈3 hours after the sheaths were removed and was stopped when the INR reached a therapeutic range. Sheaths were pulled when the activated clotting time (ACT) was <200 seconds.
On-Coumadin
Warfarin was not stopped the night before the procedure and was taken the night of the procedure. Transesophageal echocardiography was performed if patients presented to the electrophysiology laboratory with a subtherapeutic INR on the day of procedure. If INR was >3.5, patients were given 1 to 2 U of fresh-frozen plasma before the procedure. Before trans-septal catheterization puncture, an intravenous bolus of heparin 10 000 IU was administered in men and 8000 IU in women irrespective of body weight. During the procedure, ACT was checked every 20 minutes and additional heparin Boluses were administered as needed to maintain ACT >300. The trans-septal sheaths were continuously infused with heparinized saline (2000 IU/250 mL bag) during the entire procedure. After ablation was completed in the left atrium, heparin was partially reversed with protamine guided by the ACT values.
After Procedure
Warfarin was continued for at least 6 months with an INR between 2 and 3.
End Points
Primary end point of the study was change in migraine status at follow-up.
Secondary end points were (1) change in migraine status and detection of postprocedure brain-MRI lesions based on the periprocedural anticoagulation regimen, (2) change in QoL at follow-up, and (3) recurrence-free survival.
Recurrence was defined as arrhythmia (AF, atrial flutter, or atrial tachycardia) of >30-second duration off antiarrhythmic drugs at follow-up. Any episodes that occurred during the first 12 weeks (blanking period) after the procedure were not considered as recurrence. 13
Follow-Up
Patients were discharged after overnight observation after ablation. They were discharged on their previously ineffective antiarrhythmic drugs which were continued until the end of the blanking period (12 weeks) and discontinued then. In case of recurrences after the blanking period, patients were given previously ineffective antiarrhythmic drugs.
All patients were followed up for 17±5 (median 16 [Q1-Q3, 12-21]) months post ablation. Follow-up was performed at 3, 6, 9, and 12 months after the procedure, with a cardiology evaluation, a 12-lead ECG, and a 7-day holter monitoring. Additionally, patients were given event recorder for 5 months after ablation and were asked to transmit their rhythm every time they had symptoms compatible with arrhythmias and at least twice a week even if asymptomatic.
Migraine survey was conducted at 6 and 12 months after the procedure during office visits. SF-36 questionnaire was self-administered at 6 and 12 months of follow-up, either during clinic visit or e-mailed or snail-mailed to the patients for completion.
Statistical Analysis
This was an open-label prospective study assessing the change in frequency and severity of existing migraine or incidence of newonset migraine after CA for AF. Consecutive consenting patients meeting the eligibility criteria were enrolled, and based on the response to baseline, migraine survey was classified into 2 cohorts: group 1 (with positive prior migraine history) and group 2 (no history of symptomatic migraine). The primary end point of the study was change in migraine status (change in frequency or severity of migraine from baseline or new-onset migraine episodes) after CA. Assessment of pre-and postablation change in brain MRI lesions, QoL, and arrhythmia recurrence at follow-up was the secondary end points.
Continuous data were described as mean±SD and as counts and percent if categorical. Student t test and χ 2 test (Fisher exact test if n<10) were used to compare differences across groups. Paired t tests (Wilcoxon signed-rank test for non-normal data) were used to compare QoL scores and migraine parameters at baseline and follow-up. Univariate and multivariate logistic regression was used for identifying independent predictors of outcomes (cerebral atrophy, microangiopathic changes, and lacunar infarcts). Potential confounders entered into the multivariable model were identified based on known clinical relevance or significant association observed in univariate analysis. The odds ratio (OR) and 95% confidence intervals were computed. All tests were 2-sided and a P value <0.05 was considered statistically significant. Analyses were performed using SAS 9.2 (SAS Institute Inc, Cary, NC).
Results
Of the 125 patients enrolled in the study, 40 patients had prior history of migraine (group 1) and 85 patients were without migraine (group 2). At baseline, the demographic characteristics and clinical risk factors were similarly distributed across the 2 cohorts. In groups 1 and 2, the left ventricular ejection fraction was 57±9% and 58±10% (P=0.59), 75% and 73% were men (P=0.81), BMI was 32±6 and 31±6 kg/m 2 (P=0.38), 53% and 47% had hypertension (P=0.57), and 25% and 19% had CHADS2 score ≥2 (P=0.54), respectively. During the procedure, the max ACT was 390±36 and 395±46 seconds, respectively (P=0.54). The population characteristics are summarized in Table 1 .
The procedural duration and radiofrequency time were not different between group 1 and 2 (2.6±0.9 versus 2.8±1.1 hour; P=0.29 and 77±31 versus 73±33 minutes; P=0.19, respectively).
Migraine Parameters at Baseline and Follow-Up
Response to baseline and follow-up, migraine survey was available for all patients.
Among the 40 patients with history of migraine (group 1), 26 (65%) reported experiencing ≤1 episode/mo, whereas 10 (25%) patients had 2 to 9 migraine episodes and 4 (10%) had ≥10 symptoms every month, at baseline.
In group 1 at follow-up, migraine symptoms substantially decreased in all patients except 2, whose headache frequency and severity increased. These 2 patients, with <1 episode/mo at baseline, reported 3 to 4 migraine attacks per month at follow-up. Intensity of pain increased 4 to 5 scale points.
Twenty-five (63%) patients never had a symptom during follow-up. Of the 14 patients with 2 to >10 headaches/mo, 10 (25%) reported <1 episode and 3 patients (8%) reported to have 2 to 3 symptoms per month. One patient, who used to have daily symptomatic episodes (30 migraines/mo), reported 2 symptoms per month after ablation.
Similar reduction in severity of pain and duration of migraine were noted at the follow-up in group 1. The intensity of pain decreased 5 median scale points (baseline 7 [Q1-Q3, 4-8] to 2 [0-4] at follow-up; P<0.001), and duration of headache reduced from median 8 (Q1-Q3, 4-15) hours to 0.5 (Q1-Q3, 0-2) hours (P<0.001; Figure 2 ).
In group 2, only 2 of the 85 (2.4%) patients developed postprocedure new-onset migraine. These patients had 3 to 5 migraine episodes accompanied by visual aura starting within the first week after ablation.
dMRI Findings at Baseline and Follow-Up
Baseline SCIs were detected in 47 of 125 (38%) patients of which 12 (30%) were from group 1 and 35 (41%) from group 2 (P=0.23). Clinically SCIs were defined as focal, sharply demarcated areas of hyperintensity on T2/fluid-attenuated inversion recovery and hypointensity on T1-weighted images.
Mild cerebral atrophy was observed in 10 (25%) patients in group 1 and 33 (39%) in group 2 and moderate atrophy was noted in 1 (2.5%) and 6 (7.1%) patients, respectively.
Baseline dMRI showed microangiopathy-related imaging patterns (hemosiderin deposits on T2-weighted images) in 33 (26%) patients (8 [20%] in group 1 and 25 [29%] in group 2). Although majority of these lesions (27 of 33) were mild, only 6 patients showed moderate generalized microangiopathic changes (Figure 3 ). Older patients were significantly more likely to show the lesions (adjusted OR 1.3 [95% CI, 1.05-1.7]; P=0.003).
Follow-Up
The incidence of new SCIs at the postprocedure dMRI was 9.6% (12/125) in the overall study population. Two patients in group 1 and 10 in group 2 showed evidence of SCI at followup dMRI (P=0.34). Of the 2 group, 1 patient with new SCIs, migraine worsened in both.
Change in the Course of Migraine by Anitcoagulation Status
Seventy-one (57%) of the 125 patients maintained therapeutic INR on-Coumadin, whereas 54 (43%) presented with subtherapeutic INR (11 and 43 from groups 1 and 2, respectively; 17 on-Coumadin and 37 off-Coumadin). The decision to perform ablation with interrupted warfarin was taken when the patients had subtherapeutic INR and were low-risk paroxysmal AF patients.
It was an interesting observation that the 2 patients experiencing exacerbation of current migraine (group 1) and the 2 patients with new-onset migraine (group 2) had ablation performed under subtherapeutic INR.
dMRI Findings by Anticoagulation Status
Incidence of SCI in the study population exhibited significant association with the anticoagulation status. Of the 71 patients undergoing ablation with therapeutic INR on-Coumadin, 1 (1.4%) reported SCI when compared with 11 of 54 (20.4%) with subtherapeutic INR and on-or off-Coumadin on the day of the procedure (P<0.001).
The SCIs detected in 11 patients with subtherapeutic INR were multiple lacunar infarcts, ranging from 4 to 8 mm in diameter (Figure 3 ). The 1 patient on therapeutic INR had a single SCI of 3 mm diameter located in the left frontal lobe in the brain MRI. 
Change in QoL
Response to QoL survey was obtained before and 12 months after procedure for all patients. At baseline, group 1 patients reported relatively lower scores in almost all SF-36 subscales. At 12 months of follow-up, patients with successful ablation in both groups demonstrated significant improvement in all domains of QoL scale excepting bodily pain (Table 2) . Interestingly, as revealed from repeated measure analysis with baseline QoL as covariate, group 1 patients derived greater benefit when compared with group 2. Particularly, the change in role limitations because of physical health subscale was significantly greater (P=0.038); which possibly could be an effect of the regression-to-mean phenomenon.
It was important to observe that the patients, who experience AF recurrence within the follow-up period, did not show any significant improvement in QoL ( Table I in 
Recurrence of Arrhythmia
At the time of analysis, the minimum follow-up duration was 6 months and the average duration was 17±5 months. The success rate was not different between the groups; 28 of 40 (70%) in group 1 and 62 of 85 (73%) in group 2 were AF/ AT free off antiarrhythmic drug at the end of the follow-up (P=0.69).
Complications and Adverse Events
No major bleeding or thromboembolic complications were recorded during the follow-up period.
Discussion
This was the first study to examine the impact of CA and periprocedural anticoagulation regimen on the disease course of migraine in AF patients, using standardized migraine questionnaire and dMRI of brain before and after the ablation procedure. Additionally, we assessed the change in QoL after CA in the study population with SF-36 scale. Our main observations were the following: (1) among the group 1 (migraine group) population, there was a significant postablation decrease in frequency and severity of migraine in most, (2) 2 of 40 patients from group 1 (5%) experienced exacerbation of migraine after procedure and new-onset migraine with visual aura was reported by 2 of 85 (2.3%) patients from group 2 (no-migraine group), (3) all 4 patients experiencing either increased migraine severity or new-onset migraine had newly detected postprocedure SCI and had subtherapeutic INR on the procedure day, and (4) QoL improved significantly in patients with successful ablation, being more pronounced in the group with migraine history. 
Change in Migraine Status
New-onset migraine is an uncommon side-effect of AF-ablation involving TSP. 4, 7 The estimated incidence of new-onset migraine reported by Noheria et al 7 and Chilukuri et al 4 was 1.1% and 0.5%, respectively. Our results revealed the frequency to be 2.3%, which was in agreement with the abovementioned studies.
Both cases of new-onset migraine and the 2 patients with migraine aggravation in our study had subtherapeutic INR on the day of the procedure. Abnormalities of hemostasis leading to an increased thrombotic risk and modification of the protective effect of warfarin are plausible explanations for this observation. 14, 15 The association between hypercoagulability and migraine is well documented. 16 A published report by King et al 17 has described a case who presented with recurrent hemiplegic migraines associated with subtherapeutic anticoagulation and subsequent remission on reinstatement of a target INR.
Among the 40 patients with history of migraine (group 1), the majority reported either no episode after the procedure or significant reduction in severity and frequency of the headache. Although the mechanism behind postablation improvement in the migraine status is still unknown, we hereby present few reasonable explanations based on the available information unknown, we hereby present few reasonable explanations based on the available information from earlier studies.
Autonomic dysfunction is a critical factor in the pathophysiology of both migraine and AF. 18, 19 The inter-relationship between migraine and AF is demonstrated by the reported findings of increased frequency of cardiac arrhythmia recorded on ECG during migraine attacks compared with a pain-free period. 19 This brings in the next question, how does AF ablation cause relief from migraine symptoms? Chen et al 18 have shown 2 possible consequences of application of radiofrequency energy at the pulmonary vein ostia; stimulation of postganglionic efferent parasympathetic fibers and decreased efferent sympathetic nerve activity. Verma et al 20 have demonstrated that pulmonary vein antrum isolation results in vagal denervation and Appel et al 21 have reported concomitant sympathetic hyperfunction and parasympathetic hypofunction to be present in patients with migraine. Therefore, it can be safely proposed that CA of AF results in the reversal of autonomic imbalance causing elimination or improvement of clinical symptoms of migraine.
Secondly, it is known that migraineures have a significantly greater than average tendency to be aware of physical sensations. 22 Symptomatic AF is a nuisance with its range of disruptive symptoms, such as palpitation, dyspnea, chest pain, dizziness, fatigue, anxiety, and syncope or presyncope 23 and its unpredictable nature. Therefore, it is likely that the presence of AF amplifies their migraine burden by making the patients more responsive to the headache and its associated symptoms and successful CA by eliminating the arrhythmia drastically reduces the burden of migraine in them.
Brain-dMRI Findings
At baseline, patients from both groups showed silent cerebral lesions (30% in group 1 and 41% in group 2), mild cerebral atrophy (25% in group 1 and 39% in group 2), and microangiopathic changes (20% in group 1 and 29% in group 2).
Brain atrophy is often found on MRI in the elderly without any apparent neurological diseases. 24, 25 Furthermore, prior studies have reported an association between AF and brain atrophy, the association being stronger with increasing burden of the arrhythmia. 26, 27 Our study participants showing brain atrophy were older and 80% of them had non-paroxysmal AF, which explains the prevalence of brain atrophy in our study population. Similarly, age, hypertension, obesity, and abnormal glucose metabolism are known risk factors of cerebral microangiopathy, 28, 29 which justifies the incidence of this finding in our mostly elderly study population with high BMI, hypertension, and diabetes mellitus.
New lacunar infarcts were detected in 9.6% of the total population on postprocedure MRI of the brain. None of them reported a history of stroke or transient ischemic attack or had relevant abnormalities at standard neurological examination. Lacunar infarcts are small noncortical infarcts caused by occlusion of a single penetrating branch of a cerebral artery. 30 As both AF and the TSP during CA are potential causes of emboli, it is not an uncommon finding in AF patients undergoing ablation therapy. Gaita et al 31 and Herrera et al 32 have reported 14% and 7.4%, respectively, of new asymptomatic cerebral embolic lesions after CA in earlier studies.
In our series, 11 of the 12 new cerebral infarcts occurred in patients undergoing the procedure either under subtherapeutic INR or with discontinuation of warfarin in the periprocedural period. In a recently published article from our group, periprocedural interruption of warfarin or subtherapeutic INR on the day of the procedure was reported to be associated with significant increase in the prevalence of SCI. 14 Of the 12 patients with new cerebral lesions, 2 were from group 1 and the rest from group 2. A significantly greater number of patients in group 1 were incidentally on therapeutic INR and ablated on continuous Coumadin compared with group 2 (29/40, 73% in group 1 versus 42/85, 49% in group 2; P=0.02). That may explain the fewer SCI in the migraine patients.
The 1 patient that developed SCI on therapeutic INR with continuous Coumadin had a small single cerebral lesion in the left frontal lobe of the brain. This patient neither had history of migraine nor experienced new-onset migraine during follow-up. As reported earlier by our group, when CA is performed under effective anticoagulation control, it drastically reduces the prevalence of SCI. 14 Also, migrainous infarctions are reported to be mostly found in the posterior cerebral artery circulation territory 33 We observed new cerebral lesions in the postprocedure MRI of all 4 patients having either new migraine or aggravation of pre-existent migraine. Although the relationship between migraine and cerebral infarction is yet to be established, increased prevalence of these lesions has been reported in some patients with migraine with or without aura and the risk increases with increasing migraine frequency. 34 Dehydration during migraine attacks leading to formation of local thrombosis and local neurogenic inflammation and release of neuropeptides and cytokines causing tissue damage have been attributed to be contributing to the infarct formation in migraine. 34 
Improvement in QoL
We observed lower baseline scores in all SF-36 measures in group 1 than that in group 2. At 12 month of follow-up, QoL scores significantly increased in all subscales of SF-36 except bodily pain, after successful CA in both groups, the magnitude of improvement being greater in group 1 patients. AF and migraine independently cause considerable impairment in QoL. [35] [36] [37] Therefore, it is plausible that when both conditions concurrently exist, the intrusiveness of 2 diseases and their treatments would affect the health-related QoL worse than when AF is present alone. Successful ablation is known to improve QoL in AF patients, irrespective of AF type. 38 Thus, the improvement that we detected in both groups was well expected. In earlier studies, we and others observed a greater enhancement in QoL in patients having lower baseline scores, 9, 39 which rationalizes the greater degree of QoL improvement in group 1 than in group 2, in this study. Lack of substantial change in bodily pain in the SF-36 scales can be attributed to age-related comorbidities, such as osteoporosis, arthritis, joint replacement in our mostly elderly study population.
Limitations
We did not assess the affective (anxiety and depression) and cognitive functions of our study participants. Therefore, whether the detected lacunar infarcts were indeed silent or had any correlation with subtle cognitive impairment and depression could not be ascertained. Moreover, we did not obtain a repeat-MRI later in the follow-up in patients with postprocedure new lesions, which could have allowed assessment of evolution of these infarctions. Additionally, the sample size and event count were small. Therefore, the results depicting association between anticoagulation and migraine as well as between migraine and SCI need to be reaffirmed by larger prospective studies. Furthermore, because of the study design, it was not possible to exclude a potential placebo effect of the procedure. Lastly, QoL was measured by a generic questionnaire, thus we could not exclude the impact of comorbidities, such as back problems and arthritis on the physical component of the QoL score in this elderly population. Also, diseasespecific surveys would have better reflected the impact of the selected condition on life quality. However, the wealth of data and extensive validation that come with these generic tools cannot be ignored.
Conclusions
This is the first study to report significant improvement in preexistent migraine status after CA for AF in majority of patients. Additionally, successful ablation improved QoL in patients with or without migraine, but more so in the migraineures. Of note, the only cases of new migraine and aggravation of preexistent headache had a subtherapeutic INR during the procedure and had new cerebral infarcts. This observed association between migraine, SCI, and subtherapeutic INR needs to be confirmed by future studies in a larger population.
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